ClinicalTrials.gg
RecruitingNCT06525402Updated Sep 30, 2026

Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemotherapy

An interventional study of Sodium Bicarbonate Group (Usual care) and Saline Group in Oral Mucositis and Chemotherapy Effect, sponsored by Burdur Mehmet Akif Ersoy University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Burdur Mehmet Akif Ersoy University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Study summary

This study was planned as a randomized controlled experimental study in order to compare the effects of oral care with saline and black mulberry syrup in addition to sodium bicarbonate on oral mucositis level in children aged 6-18 years receiving chemotherapy.

Read the detailed description

Oral mucositis, also known as stomatitis, is the most common complication of cancer treatment. Mucositis affects the patient's nutrition, daily functions, and quality of life, may compromise the ability to tolerate scheduled therapy. For this reason, the children to be included in the study will be randomly divided into three groups. Sodium bicarbonate, which is the routine care in the clinic, will be administered to the control group, and to the intervention groups, saline in addition to the routine care and black mulberry syrup will be applied in addition to the routine care. Data will be collected according to Patient Information Form, International Child Mucositis Assessment Scale (ChIMES), World Health Organization Mucositis Classification and neutrophil counts. Oral care will be applied to the groups 4 times a day for 14 days. The International Child Mucositis Rating Scale (ChIMES), World Health Organization Mucositis Classification and neutrophil counts will be evaluated by the researchers on the 1st, 2nd, 4th, 8th and 16th days.

02

Conditions studied

  • Oral Mucositis
  • Chemotherapy Effect

Browse trials for

Keywords

  • Sodium Bicarbonate
  • Saline
  • Black Mulberry Syrup
  • Oral Mucositis
  • Chemotherapy
  • Children
03

In context

Stomatitis

306 studies on the registry are indexed under Stomatitis; 75 are open to participants now.

This study's planned enrollment of 54 is close to the median of 60 across 276 interventional studies indexed under Stomatitis.

Browse Stomatitis studies →

Lead sponsor

Burdur Mehmet Akif Ersoy University is the lead sponsor of 48 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The willingness of the family and the child to participate in the study
  • Parent and child have separately informed written consent form
  • Be between 6-18 years old
  • Receiving chemotherapy and being hospitalized for chemotherapy treatment
  • Being fed orally

Exclusion criteria

Exclusion Criteria:

  • Oral mucositis in the first intraoral evaluation
  • Having diabetes
  • Receiving radiotherapy
  • Having a surgical procedure in the mouth and jaw area
  • Receiving therapy during chemotherapy treatment
  • Using a method other than the methods used in the study to protect the oral mucous membrane throughout the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Placebo comparator
    Sodium Bicarbonate Group (Usual care)

    General routine oral care. In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group will receive routine oral care in the clinic with sodium bicarbonate. It will be applied as a 5 ml mouthwash four times a day, after meals and before going to bed at night.

    Other: Sodium Bicarbonate Group (Usual care)

  • Experimental
    Saline Group

    It will be applied as a 5 ml mouthwash four times a day, after meals and before going to bed at night.

    Other: Saline Group

  • Experimental
    Black Mulberry Syrup Group

    It will be applied as a 5 ml mouthwash four times a day, after meals and before going to bed at night.

    Other: Black Mulberry Syrup Group

Interventions

  • OtherSodium Bicarbonate Group (Usual care)

    In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group, the control group, will receive routine oral care in the clinic with sodium bicarbonate. Oral care will be applied 4 times a day for 14 days.

  • OtherSaline Group

    The second group, the experimental group, will first receive oral care routinely applied in the clinic. Then, oral care will be given in the form of 5 ml mouthwash with saline. Oral care will be applied 4 times a day for 14 days.

  • OtherBlack Mulberry Syrup Group

    The third group, the experimental group, will first receive oral care routinely applied in the clinic. Then black mulberry syrup will be applied. Then, oral care will be given in the form of 5 ml mouthwash with black mulberry syrup. Oral care will be applied 4 times a day for 14 days.

06

What researchers measure

Primary outcomes

  1. Children's International Mucositis Evaluation Scale

    Tomlison et al. (2010) developed Children's International Mucositis Evaluation Scale (ChIMES) in order to evaluate the difficulty experienced by children with cancer due to mouth/throat pain developing depending on mucositis. Yavuz et al., (2011) conducted the validity and reliability study of the Turkish version of the scale. The scale consists of six (6) questions and it is an easy-to-apply form that can be answered with the child's facial expressions.

    Time frame: up to 16 days

  2. Oral Mucositis Evaluation Index of the World Health Organization

    It is scored between zero and four points. Although there is no change in the grade-0 mucosa, grade-1 painless ulcers, erythema or mild sensitivity, grade-2 painful erythema and ulcers, solid foods can be consumed. Grade-3 painful erythema, edema or ulcer can be consumed only, grade-4 ulceration, necrosis and hemorrhage are present, the patient cannot be fed, enteral or parenteral support is required.

    Time frame: up to 16 days

Secondary outcomes

  1. Neutrophil count

    The neutrophil count will be evaluated. Numbers will be recorded.

    Time frame: up to 16 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Sep 2026, 19 months.

Of 65 non-industry interventional studies with no phase under Stomatitis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 19 months is above that.

Counting every sponsor, half of 73 studies reached it within 14 months; a quarter within 10 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2025 → Sep 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Jul 29, 2024
StartActual
Jan 30, 2025
Primary completionActual
Sep 25, 2026was Dec 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2025→Sep 25, 2026 (actual)
Sep 30, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Dec 30, 2025→Sep 25, 2026 (now actual)
    Study completion Dec 31, 2025→Dec 31, 2026
    + 4 other changes: index terms, verification date, design details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06525402
Lead sponsor
Burdur Mehmet Akif Ersoy University
Responsible party
Selda Ateş Beşirik (Assistant Professor, Burdur Mehmet Akif Ersoy University) — Principal investigator
First posted
Jul 29, 2024
Start date
Jan 30, 2025
Primary completion
Sep 25, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Selda Ateş Beşirik, Assistant Professor
Contact
seldaates07@gmail.com
+905543683323
Selda Ateş Beşirik, Assistant Professor
principal investigator · Burdur Mehmet Akif Ersoy University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion